Together, these findings underscore that LC's variable clinical efficacy arises from interacting factors including patient phenotype, dosing strategy, intervention duration, and endpoint sensitivity
Finally, following recent concerns by regulatory agencies regarding a potential increase in suicidal behavior associated with GLP-1RAs 206 , we found 1 recent pharmacovigilance report showing 0.6% suicidal events among 41,236 safety reports for these medications 207 and an emulated target trial of 86,418 older adults with T2DM that did not identify any difference in suicidal ideation or behavior between GLP-1RAs and other antidiabetic medications over 1.5 years 208
Both medications carry potential side effects, and combining them could increase the risk of adverse reactions
Haslam DW, James WPT
in the latter, they basically curb your appetite
Retatrutide Recently, a 48-week, phase 2, dose-ranging trial evaluating a novel triple-hormone receptor agonist for obesity management was published